Provided by Tiger Trade Technology Pte. Ltd.

Agenus

8.33
-1.6000-16.11%
Post-market: 8.470.1392+1.67%19:53 EDT
Volume:1.95M
Turnover:17.59M
Market Cap:375.02M
PE:3.33
High:9.99
Open:9.95
Low:8.28
Close:9.93
52wk High:10.31
52wk Low:2.71
Shares:45.02M
Float Shares:40.38M
Volume Ratio:1.41
T/O Rate:4.83%
Dividend:- -
Dividend Rate:- -
EPS(TTM):2.50
EPS(LYR):-0.0034
ROE:-1278.83%
ROA:12.53%
PB:-1.88
PE(LYR):-2,452.89

Loading ...

Immuno-oncology developer Agenus' Q1 revenue rises, posts profit

Reuters
·
May 11

Press Release: Agenus Reports First Quarter 2026 Financial Results and Highlights BOT+BAL Execution Across Global Access and Phase 3 Development

Dow Jones
·
May 11

Agenus Q1 FY26 net income swings to $39.2 million; revenue rises to $33.7 million

Reuters
·
May 11

Agenus Q1 Revenue USD 4.6 Million

THOMSON REUTERS
·
May 11

Corrected-Agenus Q1 Revenue USD 33.7 Million (Corrects Amount)

THOMSON REUTERS
·
May 11

Agenus Reports First Quarter 2026 Financial Results and Highlights BOT+Bal Execution Across Global Access and Phase 3 Development

THOMSON REUTERS
·
May 11

Agenus Inc expected to post earnings of $2.10 a share - Earnings Preview

Reuters
·
May 08

Agenus to report first-quarter results before market open

Reuters
·
May 05

Agenus to Provide First Quarter 2026 Financial Report and Corporate Update

THOMSON REUTERS
·
May 05

Agenus to present first Phase 2 botensilimab melanoma data at ASCO 2026

Reuters
·
Apr 21

Agenus names BAP Pharma exclusive global partner for botensilimab-balstilimab access programs

Reuters
·
Apr 21

Agenus announces annual shareholder meeting webcast

Reuters
·
Apr 21

Agenus reports Phase 2 results from BOT and BAL with agenT-797

TIPRANKS
·
Apr 18

BRIEF-Agenus Reports Phase Ii Data Demonstrating Immune Reprogramming And Durable Survival With Botensilimab, Balstilimab And Agent-797 In Pd-1 Refractory Gastroesophageal Cancer

Reuters
·
Apr 18

Agenus reports Phase II data showing 77% disease control in PD-1 refractory gastroesophageal cancer

Reuters
·
Apr 18

Agenus Inc - Study Does Not Meet Primary Endpoint of Objective Response Rate

THOMSON REUTERS
·
Apr 18

Agenus to present Phase II BOT+BAL plus agenT-797 data in PD-1 refractory GEC at AACR

Reuters
·
Apr 03

Agenus Announces Data From Phase Ii Study of BOT+Bal in Combination With Agent-797 in Pd-1 Refractory Gastroesophageal Cancer to Be Presented at Aacr 2026

THOMSON REUTERS
·
Apr 03